Literature DB >> 6661364

Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.

M J Brodie, G Forrest, W G Rapeport.   

Abstract

Steady state carbamazepine (CBZ) plasma concentrations were similar in 15 epileptics receiving monotherapy and in 24 patients taking CBZ in combination with one other anticonvulsant. The ratio of CBZ 10, 11-epoxide (CBZ-E) to the parent drug was significantly higher (P less than 0.01) in those patients taking concomitant phenytoin (n = 9), phenobarbitone or primidone (n = 9), and valproic acid (n = 6) than in the patients receiving CBZ alone. In the monotherapy group, there was a significant correlation between CBZ-E/CBZ ratio and the concentration of the parent drug (P less than 0.05). If CBZ-E has equipotent anticonvulsant properties to CBZ in man as is the case in animal models, routine CBZ-E concentrations may provide further refinement in the therapeutic drug monitoring of CBZ.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661364      PMCID: PMC1428363          DOI: 10.1111/j.1365-2125.1983.tb02257.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography.

Authors:  M Eichelbaum; L Bertilsson
Journal:  J Chromatogr       Date:  1975-01-14

2.  Effect of phenobarbital and 3-methylcholanthrene administration on epoxide hydrase levels in liver microsomes.

Authors:  E Bresnick; H Mukhtar; T A Stoming; P M Dansette; D M Jerina
Journal:  Biochem Pharmacol       Date:  1977-05-01       Impact factor: 5.858

3.  Induction effect of phenobarbital on the carbamazepine to carbamazepine-10, 11-epoxide pathway in rhesus monkeys.

Authors:  I H Patel; P Wedlund; R H Levy
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

4.  Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain.

Authors:  P L Morselli; A Baruzzi; M Gerna; L Bossi; M Porta
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

5.  Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.

Authors:  M L Friis; J Christiansen; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

6.  Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

Authors:  J J MacKichan; P K Duffner; M E Cohen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

8.  Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy.

Authors:  M Eichelbaum; K W Köthe; F Hoffman; G E von Unruh
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

9.  Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma.

Authors:  L McKauge; J H Tyrer; M J Eadie
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

10.  Pharmacokinetics of Carbamazepine in man: a review.

Authors:  S Pynnönen
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

View more
  15 in total

Review 1.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

2.  Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine.

Authors:  D K Robbins; P J Wedlund; R Kuhn; R J Baumann; R H Levy; S L Chang
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 3.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

5.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

6.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

7.  Controlled evaluation of a supplementary dose of carbamazepine on psychomotor function in epileptic patients.

Authors:  G J Macphee; E M McPhail; E Butler; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Carbamazepine 10,11-epoxide in children.

Authors:  G W Rylance; C Edwards; P R Gard
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 9.  Pharmacokinetic optimisation of anticonvulsant therapy.

Authors:  A H Thomson; M J Brodie
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

10.  Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients.

Authors:  R A Gillham; N Williams; K Wiedmann; E Butler; J G Larkin; M J Brodie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.